Table 3

Net cost of iMDA* per case averted and per death averted by country under two ivermectin efficacy levels

Net cost (US$)(A) Per case averted(B) Per death averted
Griffin scenarioSustainNo changeAccelerate1Accelerate2InnovateSustainNo changeAccelerate1Accelerate2Innovate
Efficacy 40%
 Burkina Faso−201712−531−8441124033895
 Mali−102712−91675123957829139
 Niger013915−227545157153398041
 COD†135111858116233221871012 503
 Mozambique2351319101921203909990013 979
 Nigeria246142013782452429010 30914 353
 Uganda246142122993996693016 50422 920
 Ghana6912213041955437819216 34721 463
 Tanzania21263149657505846811 63919 93624 636
Efficacy 20%
 Burkina Faso912152535265332774795914911 815
 Mali9121627376297133011 17121 06727 087
 Niger111418304156586760967817 82322 703
 COD†1417213547902210 53614 84626 60233 513
 Mozambique151923375010 17811 79216 52029 30636 765
 Nigeria162025395310 53212 11916 89329 69937 117
 Uganda172125405416 79719 44626 90147 25659 036
 Ghana253036557316 23918 15424 77041 84451 394
 Tanzania55647410914119 21120 82927 75844 74653 768
  • All net costs are inflation-adjusted to 2020 US$ and simulated based on severity=3% and ‘Rapid’ uptake level.

  • *iMDA: ivermectin mass drug administration.

  • †COD: Democratic Republic of the Congo.